Giulia KennedyPhD
The Journal of Clinical Endocrinology & Metabolism · 2021

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules

Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT

Co-authorverifiedThyroid nodule genomic classification
Journal
The Journal of Clinical Endocrinology & Metabolism · vol. 106 · no. 8 · pp. 2198-2207
Published
13 Jul 2021

Synopsis

Real-world molecular findings from consecutive Bethesda III-VI thyroid fine-needle aspirates tested with the Afirma GSC and Xpression Atlas: of 48,952 Bethesda III/IV aspirates, 66% were benign by the GSC. Kennedy is fifteenth of sixteen authors, before Richard T. Kloos.

In the career genome

  • VeracyteChapter 10 · Strand B · Publication
    Veracyte, Inc.

    Afirma GSC and the Xpression Atlas

    Chief Scientific Officer and Chief Medical Officer, Veracyte

    MAY 2017 – SEP 2022